

Cover Story
Editorial
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
In Brief


Clinical Roundup


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
















